Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
3.80% $39.02
America/New_York / 23 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 2 909.34 mill |
EPS: | -1.960 |
P/E: | -19.91 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 74.56 mill |
Avg Daily Volume: | 0.708 mill |
RATING 2024-04-23 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Sell | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -19.91 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-3.39x |
Company: PE -19.91 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.114 (-100.29%) $-39.13 |
Date: 2024-04-24 |
Expected Trading Range (DAY) |
---|
$ 37.30 - 40.74 ( +/- 4.41%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-01 | Hata Yujiro S | Buy | 480 000 | Stock Option (right to buy) |
2024-03-01 | Ruiz Briseno Andres | Buy | 85 000 | Stock Option (right to buy) |
2024-03-01 | Beaupre Darrin | Buy | 160 000 | Stock Option (right to buy) |
2024-03-01 | White Michael Anthony | Buy | 140 000 | Stock Option (right to buy) |
2024-03-01 | Throne Jason | Buy | 125 500 | Stock Option (right to buy) |
INSIDER POWER |
---|
41.91 |
Last 100 transactions |
Buy: 2 399 671 | Sell: 963 791 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $39.02 (3.80% ) |
Volume | 0.486 mill |
Avg. Vol. | 0.708 mill |
% of Avg. Vol | 68.62 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $44.99 | N/A | Active |
---|
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.